FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018220012> ?p ?o ?g. }

• W2018220012 endingPage "380" @default.
• W2018220012 startingPage "376" @default.
• W2018220012 abstract "<h3>Background</h3> Immune-checkpoint blockade (ICB) therapies have transformed the treatment landscapes of hepatocellular carcinoma (HCC). Despite unprecedented success in clinical trials, the immunosuppressive tumor microenvironment (TME) constructed by tumor cells restricts the responsiveness of ICB therapies to a minority of patients. Triggering receptor expressed on myeloid cells-2 (TREM2) counteracts inflammation and maintains metabolic fitness in myeloid cells. Emerging single-cell RNA sequencing (scRNA-seq) data in different types of tumors have identified the significance of TREM2⁺myeloid cells in tumor development and ICB resistance. In this study, we aimed to investigate the potential role of TREM2 in HCC ICB resistance and to identify intrinsic regulators within the TME that promote TREM2 expression and function. <h3>Methods</h3> We conducted scRNA-seq of tumor biopsies in a phase II clinical trial of pembrolizumab (anti-PD1) on advanced HBV-related HCC patients (NCT03419481) to delineate the distinct myeloid landscape of the TME between ICB-responsive and non-responsive HCC. Two syngeneic ICB-resistant and sensitive HCC mouse models were used to validate the clinical findings and explore the potential role of TREM2 involved in HCC ICB resistance. Bone marrow-derived macrophage was used to explore the regulation of tumor cells on myeloid Trem2 expression. Furthermore, we constructed myeloid cell targeting short-hairpin RNA (shRNA) lentiviruses against Trem2 (shTrem2) to down-regulate Trem2 in vitro and in vivo. <h3>Results</h3> scRNA-seq analysis of our pembrolizumab trial on advanced HCC identified a subset of tumor-associated macrophages over-expressing TREM2 in non-responders. Consistently, our syngeneic ICB-resistant HCC mouse models verified a group of Trem2⁺myeloid cells, which were accumulated in the lipid-rich TME of ICB-resistant tumors. Compared to the parental ICB-sensitive tumor cells, the conditional medium (CM) of ICB-resistant tumor cells significantly increased Trem2 expression in macrophages, which was abolished when lipids in the CM were depleted. Notably, lentivirus-mediated Trem2 ablation reduced lipid accumulation in TME and overcame anti-PD-1 resistance with increased cytotoxic CD8⁺T cell infiltration. <h3>Conclusions</h3> Our study highlights TREM2 as an immuno-metabolic target to enhance HCC immunotherapy." @default.
• W2018220012 created "2016-06-24" @default.
• W2018220012 creator A5004075845 @default.
• W2018220012 creator A5031125947 @default.
• W2018220012 creator A5056591092 @default.
• W2018220012 creator A5075731635 @default.
• W2018220012 creator A5077819564 @default.
• W2018220012 date "2004-02-09" @default.
• W2018220012 modified "2023-09-29" @default.
• W2018220012 title "DWI abnormalities and clinical characteristics in TIA patients" @default.
• W2018220012 cites W1971313531 @default.
• W2018220012 cites W1974893560 @default.
• W2018220012 cites W1996772474 @default.
• W2018220012 cites W1998450323 @default.
• W2018220012 cites W2006082306 @default.
• W2018220012 cites W2007861811 @default.
• W2018220012 cites W2028910996 @default.
• W2018220012 cites W2034001244 @default.
• W2018220012 cites W2037066130 @default.
• W2018220012 cites W2042215125 @default.
• W2018220012 cites W2044022206 @default.
• W2018220012 cites W2050188772 @default.
• W2018220012 cites W2067017818 @default.
• W2018220012 cites W2073889782 @default.
• W2018220012 cites W2098483944 @default.
• W2018220012 cites W2099708759 @default.
• W2018220012 cites W2100186853 @default.
• W2018220012 cites W2106552966 @default.
• W2018220012 cites W2108085568 @default.
• W2018220012 cites W2111089169 @default.
• W2018220012 cites W2123617965 @default.
• W2018220012 cites W2124260270 @default.
• W2018220012 cites W2141069270 @default.
• W2018220012 cites W2156842422 @default.
• W2018220012 cites W2160768922 @default.
• W2018220012 cites W2168891925 @default.
• W2018220012 cites W2610686450 @default.
• W2018220012 cites W2767911074 @default.
• W2018220012 doi "https://doi.org/10.1212/01.wnl.0000110303.57683.3a" @default.
• W2018220012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14872016" @default.
• W2018220012 hasPublicationYear "2004" @default.
• W2018220012 type Work @default.
• W2018220012 sameAs 2018220012 @default.
• W2018220012 citedByCount "108" @default.
• W2018220012 countsByYear W20182200122012 @default.
• W2018220012 countsByYear W20182200122013 @default.
• W2018220012 countsByYear W20182200122014 @default.
• W2018220012 countsByYear W20182200122015 @default.
• W2018220012 countsByYear W20182200122016 @default.
• W2018220012 countsByYear W20182200122017 @default.
• W2018220012 countsByYear W20182200122019 @default.
• W2018220012 countsByYear W20182200122022 @default.
• W2018220012 countsByYear W20182200122023 @default.
• W2018220012 crossrefType "journal-article" @default.
• W2018220012 hasAuthorship W2018220012A5004075845 @default.
• W2018220012 hasAuthorship W2018220012A5031125947 @default.
• W2018220012 hasAuthorship W2018220012A5056591092 @default.
• W2018220012 hasAuthorship W2018220012A5075731635 @default.
• W2018220012 hasAuthorship W2018220012A5077819564 @default.
• W2018220012 hasConcept C173396325 @default.
• W2018220012 hasConcept C190232843 @default.
• W2018220012 hasConcept C203014093 @default.
• W2018220012 hasConcept C2776107976 @default.
• W2018220012 hasConcept C2777701055 @default.
• W2018220012 hasConcept C2778019345 @default.
• W2018220012 hasConcept C2779282312 @default.
• W2018220012 hasConcept C2779685842 @default.
• W2018220012 hasConcept C2780851360 @default.
• W2018220012 hasConcept C2994430510 @default.
• W2018220012 hasConcept C3020616263 @default.
• W2018220012 hasConcept C502942594 @default.
• W2018220012 hasConcept C54355233 @default.
• W2018220012 hasConcept C71924100 @default.
• W2018220012 hasConcept C81885089 @default.
• W2018220012 hasConcept C86803240 @default.
• W2018220012 hasConcept C8891405 @default.
• W2018220012 hasConceptScore W2018220012C173396325 @default.
• W2018220012 hasConceptScore W2018220012C190232843 @default.
• W2018220012 hasConceptScore W2018220012C203014093 @default.
• W2018220012 hasConceptScore W2018220012C2776107976 @default.
• W2018220012 hasConceptScore W2018220012C2777701055 @default.
• W2018220012 hasConceptScore W2018220012C2778019345 @default.
• W2018220012 hasConceptScore W2018220012C2779282312 @default.
• W2018220012 hasConceptScore W2018220012C2779685842 @default.
• W2018220012 hasConceptScore W2018220012C2780851360 @default.
• W2018220012 hasConceptScore W2018220012C2994430510 @default.
• W2018220012 hasConceptScore W2018220012C3020616263 @default.
• W2018220012 hasConceptScore W2018220012C502942594 @default.
• W2018220012 hasConceptScore W2018220012C54355233 @default.
• W2018220012 hasConceptScore W2018220012C71924100 @default.
• W2018220012 hasConceptScore W2018220012C81885089 @default.
• W2018220012 hasConceptScore W2018220012C86803240 @default.
• W2018220012 hasConceptScore W2018220012C8891405 @default.
• W2018220012 hasIssue "3" @default.
• W2018220012 hasLocation W20182200121 @default.
• W2018220012 hasLocation W20182200122 @default.
• W2018220012 hasOpenAccess W2018220012 @default.
• W2018220012 hasPrimaryLocation W20182200121 @default.

• next